Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis

What Was Tested

The paper reports a study of Relamorelin, published as a randomized controlled trial.

Gastroparesis is an important complication of diabetes.

The researchers investigated the effects of relamorelin (a pentapeptide-selective agonist of the ghrelin receptor that speeds gastric emptying in patients with diabetes) in patients with diabetic gastroparesis.

Who Took Part

The study group was 204 patients.

PubMed indexes the participants as middle-aged adults, both men and women.

Secondary end points included nausea, abdominal pain, bloating, early satiety, as well as the composite score of these 4 subjective symptoms and vomiting frequency and severity.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Relamorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Relamorelin study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Relamorelin group a baseline to be compared against.

The primary end point was the half-time of gastric emptying.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Gastric Emptying, Gastroparesis, Oligopeptides and Vomiting.

The authors tagged it with the keywords Gastrointestinal Motility, Phase 2 Trial and RM-131.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Relamorelin in 204 patients.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (Gastroenterology), a journal based in United States.

More context: the Relamorelin compound page, all human trials.